INTRANASAL ADMINISTRATION FOR A SUSTAINED BRAIN DELIVERY OF HIGHLY PROTEIN-BOUND
The present invention discloses a composition comprising a drug highly binding to plasma proteins for use in the treatment of central nervous system disorders, particularly psychiatric, neurological or neurodegenerative diseases, depression, post-traumatic stress, obsessive-compulsive disorder, pani...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
15.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention discloses a composition comprising a drug highly binding to plasma proteins for use in the treatment of central nervous system disorders, particularly psychiatric, neurological or neurodegenerative diseases, depression, post-traumatic stress, obsessive-compulsive disorder, panic disorder, premenstrual dysphoric disorder, social anxiety disorder or any other central nervous system disease with neuroinflammation, wherein the route of administration is intranasal. It also discloses a formulation and a device for brain sustained delivery of a selective serotonin reuptake inhibitor, particularly sertraline, and an anti-inflammatory drug, piroxicam.
La présente invention concerne une composition comprenant un médicament à forte liaison protéique pour le traitement des troubles du système nerveux central, en particulier les maladies psychiatriques, neurologiques ou neurodégénératives, la dépression, le stress post-traumatique, le trouble obsessionnel compulsif, le trouble panique, le trouble dysphorique prémenstruel, le trouble d'anxiété sociale ou toute autre maladie du système nerveux central avec neuro-inflammation, la voie d'administration étant intranasale. L'invention concerne également une formulation et un dispositif pour l'administration soutenue dans le cerveau d'un inhibiteur sélectif de réabsorption de la sérotonine, en particulier la sertraline, et d'un médicament anti-inflammatoire, le piroxicam. |
---|---|
Bibliography: | Application Number: WO2022IB61847 |